Background: Mitotic deregulations may contribute significantly to cell division errors and the development of aggressive tumor cells. The mitotic kinase Aurora B is essential for chromosome segregation. Its gene is located at 17p13 in close proximity to the TP53 gene. Although the frequent alteration of this locus is well known, the information about the AURKB status and protein expression is limited. Methods: 50 breast carcinoma cases were evaluated for 17p13 status and chromosome 17 ploidy by FISH and for Aurora B protein by immunohistochemistry. Results: Aurora B protein expression showed a strong correlation with cell proliferation (regression coefficient = 0.77). Therefore, the Aurora B/MIB-1 index was used as a measure of expression, which showed a wide range (1–35%, mean 0.32, SD ± 0.28). A gain in the 17p13 chromosome locus could not be shown while a deletion was stated in 10/50 cases including a subset with TP53 and AURKB codeletion in 6/10 cases. The loss of TP53/AURKB loci strongly correlated with aneusomy (p < 0.0001). Conclusion: Elevated Aurora B expression frequently occurs due to an increased cell proliferation rate in breast carcinoma. Codeletion of TP53 and AURKB at 17p13 indicates a concerted mechanism leading to the survival of cell clones with deficient mitotic kinase function which could contribute to the formation of aneuploid cells and an aggressive tumor phenotype.

Keywords:
Aurora kinase B, p53 antigens, Kinase deregulation, Cell proliferation, Aneuploidy
1.
Mendelin J, Grayson M, Wallis T, Visscher DW: Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. Lab Invest 1999;79:387–393.
2.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57–70.
3.
Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001;2:21–32.
4.
Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927–936.
5.
Carmena M, Earnshaw WC: The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842–854.
6.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998;396:643–649.
7.
Lukasiewicz KB, Lingle WL: Aurora A, centrosome structure, and the centrosome cycle. Environ Mol Mutagen 2009;50:602–619.
8.
Marumoto T, Zhang D, Saya H: Aurora-A – a guardian of poles. Nat Rev Cancer 2005;5:42–50.
9.
Bolanos-Garcia VM: Aurora kinases. Int J Biochem Cell Biol 2005;37:1572–1577.
10.
Katayama H, Brinkley WR, Sen S: The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451–464.
11.
Vader G, Medema RH, Lens SM: The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006;173:833–837.
12.
Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M: Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002;62:5168–5177.
13.
Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, Terada Y: Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811–4816.
14.
Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y: Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008;14:4455–4462.
15.
Carvajal RD, Tse A, Schwartz GK: Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869–6875.
16.
Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293–325.
17.
Attardi LD, Jacks T: The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999;55:48–63.
18.
Watters AD, Going JJ, Cooke TG, Bartlett JM: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109–114.
19.
Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 2003;43:354–362.
20.
Chieffi P, Cozzolino L, Kisslinger A, et al: Aurora B expression directly correlates with prostate cancer malignancy and influences prostate cell proliferation. Prostate 2006;66:326–333.
21.
Hontz AE, Li SA, Lingle WL, Negron V, Bruzek A, Salisbury JL, Li JJ: Aurora A and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res 2007;67:2957–2963.
22.
Sorrentino R, Libertini S, Pallante PL, et al: Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005;90:928–935.
23.
Seitz S, Poppe K, Fischer J, Nothnagel A, Estevez-Schwarz L, Haensch W, Schlag PM, Scherneck S: Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 2001;194:318–326.
24.
Sankar M, Tanaka K, Kumaravel TS, Arif M, Shintani T, Yagi S, Kyo T, Dohy H, Kamada N: Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia 1998;12:510–516.
25.
Takehisa M, Sasa M, Bando Y, Hirose T, Morimoto T, Nagao T, Tangoku A: Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res 2007;27:1073–1078.
26.
Tsukamoto F, Miyoshi Y, Egawa C, Kasugai T, Takami S, Inazawa J, Noguchi S: Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 2001;93:165–170.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.